Eurocine Vaccines AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private, Subsidiary
- Employees
- 3
- Market Cap
- -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunoseâ„¢ FLU in Older Adults
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: PlaceboBiological: Immunose™ FLU 2%, 300 μlBiological: Immunose™ FLU 2%, 200 μlBiological: Immunose™ FLU 1%Biological: Influenza antigenBiological: i.m comparator
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Eurocine Vaccines AB
- Target Recruit Count
- 298
- Registration Number
- NCT03437304
- Locations
- 🇸🇪
Site 3, Malmö, Sweden
🇸🇪Site 1, Uppsala, Sweden
🇸🇪Site 5, Borås, Sweden
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunoseâ„¢ FLU
Phase 1
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: Placebo, SalineBiological: intranasal comparatorBiological: 15 µg HA/strainBiological: intramuscular comparatorBiological: 15 µg HA/strain and 1% Endocine™Biological: 15 µg HA/strain and 2% Endocine™
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Eurocine Vaccines AB
- Target Recruit Count
- 162
- Registration Number
- NCT02998996
- Locations
- 🇸🇪
Site 1, Uppsala, Sweden
🇸🇪Site 2, Linkoping, Sweden
© Copyright 2025. All Rights Reserved by MedPath